SGA / Partial D2/D3·Psychiatry - Oral Antipsychotics

Cariprazine

Schizophrenia in adults

Authority requiredPBSSGAReagila1.5 mg+2

No source link confirmed for this record yet. Its own source notes are under Additional.

At a glance

Max Dose

6 mg/day

Caution: Half-life

1-3 WEEKS

Caution: Akathisia

HIGH RISK

D3 Affinity

UNIQUE

Cautions

Avoid / Cautions

Concurrent use of strong CYP3A4 inhibitors or inducers. Pregnancy Category D (Based on animal toxicity data).

Where it stands

Rapid Summary

Overview

Unique partial agonist with a massive affinity for the Dopamine D3 receptor over the D2 receptor. Targets negative and cognitive symptoms of schizophrenia. Exceptionally long half-life.

Clinical Focus

Active metabolites last up to 3 weeks in the blood. Side effects (like severe akathisia) can appear weeks after a dose change, and persist for weeks after the drug is ceased.

Bottom Line

Cariprazine is a partial D3-preferring dopamine agonist effective for bipolar depression and schizophrenia negative symptoms, but has a very long effective half-life (2-3 weeks) due to active metabolites.

Formulation & Access

Brand Names

Reagila

Oral Routes

Capsules (1.5 mg, 3 mg, 4.5 mg, 6 mg).

Prescribing & PBS

Authority Required (PBS).

Indications & Use

Primary

PBSTGA

Schizophrenia in adults.

Clinical Place

Highly valued for patients struggling with negative symptoms (apathy, anhedonia, poor motivation) due to its unique D3 receptor action.

Quick reference

Class & Role

SGA / Partial D2/D3 — Unique partial agonist with a massive affinity for the Dopamine D3 receptor over the D2 receptor.

Route / Formulation

Capsules (1.5 mg, 3 mg, 4.5 mg, 6 mg). (Reagila)

Usual Dose & Max

Start PO 1.5 mg OD. Titrate slowly (e.g., every 1-2 weeks) to 3-6 mg/day. Max 6 mg/day.

Key Indication Doses

Schizophrenia: Start PO 1.5 mg OD. Titrate slowly (e.g., every 1-2 weeks) to 3-6 mg/day. Bipolar Mania: Start PO 1.5 mg OD. Titrate to 3-6 mg/day. Renal / Hepatic: Avoid if severe renal (eGFR < 30) or severe hepatic impairment.

Best Uses

Key Risks

Neurological: Severe Akathisia (up to 20% incidence, often delayed onset). HIGH — Extrapyramidal symptoms (EPS), insomnia. Metabolic: Generally weight-neutral and lipid-neutral. Cardiovascular: Minimal effect on QTc or BP.

Key Interactions

Strong CYP3A4 inhibitors (Clarithromycin, Ketoconazole) require the Cariprazine dose to be halved. CYP3A4 inducers (Carbamazepine) will completely destroy blood levels; avoid combination.

Monitoring

Monitor closely for akathisia. Because of the 3-week half-life, you must wait 2-3 weeks between dose increases to accurately assess the patient's true steady-state tolerance. Routine BSL and Weight.

Clinical Pearl

Standard antipsychotics block D2 to stop hallucinations, but this worsens apathy and motivation. Cariprazine's unique D3 partial-agonism gently stimulates the brain's reward centers, waking the patient up and restoring emotional drive.

Access

Authority requiredReagila1.5 mg

Brand: Reagila
PBS status: Authority required
Formulation: Capsules (1.5 mg, 3 mg, 4.5 mg, 6 mg).

From this page

No calculator, monitoring schedule or factsheet is linked to this medicine page yet.